Skip to main content
. 2018 Jun 26;9:441. doi: 10.3389/fneur.2018.00441

Table 1.

Demographic and baseline clinical information of healthy controls and patients with Parkinson's disease with or without comorbid RBD and/or depression.

Groups Healthy controls (n = 31) DEP+RBD+ (n = 14) DEP-RBD+ (n = 16) DEP+RBD- (n = 43) DEP-RBD- (n = 20) p-Value** p-Value (between PD groups)**
Age (mean ± sd) 58.0 ± 12.1 58.8 ± 9.8 59.2 ± 11.6 58.5 ± 8.7 58.4 ± 9.4 0.997 0.997
Female/Male no. 18/13 11/3 12/4 24/19 13/7 0.441 0.441
Handedness (L/R) 3/28 0/14 2/14 4/36 3/17 0.717 0.716
Education years (mean ± sd) 15.0 ± 2.8 15.1 ± 2.4 16.2 ± 2.6 15.0 ± 3.0 14.8.±3.1 0.611 0.611
Duration of disease in years (mean ± sd) 7.5 ± 7.5 8.5 ± 7.5 6.2 ± 6.7 6.3 ± 6.8 0.738
Hoehn & Yahr stage (mean ± sd) 1.8 ± 0.4 1.5 ± 0.5 1.4 ± 0.5 1.7 ± 0.5 0.146
UPDRS III* (mean ± sd) 21.7 ± 8.3 21.8 ± 11.4 19.3 ± 7.3 24.7±.8.7 0.163
MOCA* score (mean ± sd) 28.4 ± 1.1 27.4 ± 2.2 27.5 ± 1.8 27.6 ± 1.8 27.6 ± 2.4 0.324 0.955
RBD* score (mean ± sd) 3.4 ± 2.1 7.4 ± 2.0 7.1 ± 1.4 2.5 ± 1.1 2.3 ± 1.1 <0.001 <0.001
GDS* score (mean ± sd) 4.4 ± 1.1 5.1 ± 0.9 3.2 ± 1.1 5.2 ± 0.4 3.3 ± 1.1 <0.001 <0.001
ESS* scale (mean ± sd) 6.7 ± 4.3 7.4 ± 3.1 7.5 ± 3.8 5.5 ± 3.2 6.2 ± 3.0 0.263 0.126
UPSIT (mean ± sd) 33.1 ± 4.3 21.6 ± 9.9 19.6 ± 8.4 24.8 ± 8.1 24.3 ± 6.8 <0.001 0.145
*

UPDRS III, Unified Parkinson's Disease Rating Scale part III; ESS, Epworth Sleepiness Scale; MoCA, Montreal Cognitive Assessment; RBD, REM sleep Behaviour Disorder Screening Questionnaire; GDS, Geriatric Depression Scale; UPSIT, the University of Pennsylvania Smell Identification Test (UPSIT).

**

p-value of one-way ANOVA analysis for age, education years, disease duration, and UPSIT; Pearson Chi-square for gender, handedness, and H&Y stage; and Kruskal–Wallis test for ESS, UPRDS part III, GDS scale, MoCA score, and RBDSQ. P < 0.05 are considered statistically significant.